Compare Davita Inc (DVA) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Impinj Inc — how do they compare? Davita Inc trades at $230.35 (market cap $14.92B), while Impinj Inc trades at $147.48 (market cap $4.40B). The key difference: Davita Inc is far larger — about 3.4× Impinj Inc's market cap, and Davita Inc is trading nearer its 52-week high, Impinj Inc nearer its low. Which is the better fit depends on your goals.
| DVA | PI | |
|---|---|---|
Market Cap | $14.92B | $4.40B |
Sector | Health | Technology |
52-Week High | $235.71 | $241.91 |
52-Week Low | $103.87 | $91.34 |
Enterprise Value | $27.47B | $4.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Impinj (PI) trades at $146.02, up 1.38% with a bullish technical signal supported by moving averages. The company shows mixed fundamentals with a negative net income margin of -7.66% but beat Q1 2026 EPS estimates. Revenue remains stable at $361M annually, though profitability challenges persist with elevated valuation ratios like P/S of 11.89. Analyst consensus is strongly bullish with 73% buy ratings and a $167.50 price target.
Outlook remains cautiously optimistic given strong analyst support and technical momentum, but investors face risks from insider selling and ongoing profitability challenges. The stock offers potential upside to consensus targets if execution improves, though negative margins and competitive pressures warrant careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
